Mead Johnson Nutrition has sold its US$1.5bn debt in a three-part sale, the company said on Friday (30 October).
The offering included $500m of 3.50% notes due 2014 priced at 99.552% of the principal amount and $700m of 4.90% notes due 2019 priced at 99.649% of the principal amount.
It also included $300m of 5.90% notes due 2039 priced at 99.973% of the principal amount.
Proceeds from the offering are intended to be used to repay debt owed to a subsidiary of Bristol-Myers Squibb Company.
The sale of the notes is expected to close on or about 5 November, the company said.

US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData